In this respect, PBP‐NPs containing HO‐1 inducers have a strong potential as safe and efficient nanotherapeutics for curing and preventing obesity, obesity‐induced metabolic syndromes, and NASH in future clinical studies. Here, HMOX1 is linked to obesity due to melanocortin 4 receptor deficiency.